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Extracellular matrixFibroblasts are the predominant cell type in the cardiac interstitium. As the main matrix-producing cells in
the adult mammalian heart, ﬁbroblasts maintain the integrity of the extracellular matrix network, thus pre-
serving geometry and function. Following myocardial infarction ﬁbroblasts undergo dynamic phenotypic al-
terations and direct the reparative response. Due to their strategic location, cardiac ﬁbroblasts serve as
sentinel cells that sense injury and activate the inﬂammasome secreting cytokines and chemokines. During
the proliferative phase of healing, infarct ﬁbroblasts undergo myoﬁbroblast transdifferentiation forming
stress ﬁbers and expressing contractile proteins (such as α-smooth muscle actin). Mechanical stress,
transforming growth factor (TGF)-β/Smad3 signaling and alterations in the composition of the extracellular
matrix induce acquisition of the myoﬁbroblast phenotype. In the highly cellular and growth factor-rich envi-
ronment of the infarct, activated myoﬁbroblasts produce matrix proteins, proteases and their inhibitors reg-
ulating matrix metabolism. As the infarct matures, “stress-shielding” of myoﬁbroblasts by the cross-linked
matrix and growth factor withdrawal may induce quiescence and ultimately cause apoptotic death. Because
of their critical role in post-infarction cardiac remodeling, ﬁbroblasts are promising therapeutic targets fol-
lowing myocardial infarction. However, the complexity of ﬁbroblast functions and the pathophysiologic het-
erogeneity of post-infarction remodeling in the clinical context discourage oversimpliﬁed approaches in
clinical translation. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac Pathways
of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Fibroblasts are the most abundant interstitial cells in the adult
mammalian myocardium [1,2]. As the main producers of extracellular
matrix proteins, ﬁbroblasts are responsible for maintaining the integ-
rity of the cardiac matrix network, thus preserving cardiac geometry.
Although direct evidence on the role of ﬁbroblasts in normal cardiac
function is lacking, it has been suggested that resident cardiac ﬁbro-
blasts may regulate the transmission of mechanical and electrical sig-
nals, thus contributing to normal systolic and diastolic function of the
ventricle [3]. Because ﬁbroblasts are typically activated following in-
jury their role as reparative cells is widely recognized and has been
extensively studied. Practically every form of heart disease is associated
with expansion and activation of the cardiac ﬁbroblast compartment.
Thus, ﬁbroblasts play a critical role in remodeling of the heart followingdiomyocyte Biology: Cardiac
tion.
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rights reserved.injury and are key regulators of cardiac geometry and function in awide
variety of cardiac conditions.
Because the adult mammalian heart has negligible regenerative
capacity, death of a large number of cardiomyocytes during acute in-
farction triggers an inﬂammatory/reparative response that effectively
debrides the necrotic tissue and ultimately heals the heart by forming
a collagen-based scar [4]. Post-infarction cardiac repair is a superbly
orchestrated process: impairment of any aspect of the reparative re-
sponse has catastrophic consequences, leading to cardiac rupture, for-
mation of ventricular aneurysms, myocardial ﬁbrosis, or chamber
dilation [5]. Adverse dilative remodeling following myocardial infarc-
tion is associated with increased mortality and a high incidence of
ventricular arrhythmias and heart failure [6]. It is widely recognized
that ﬁbroblasts are critically involved in the reparative response fol-
lowing myocardial infarction and are implicated in the pathogenesis
of cardiac remodeling [7,8]. What is less appreciated is the wide
range of dynamic functional and phenotypic alterations exhibited by
ﬁbroblasts in the infarcted heart (Table 1). The strategic location of ﬁ-
broblasts in the cardiac interstitium and their functional versatility
allow them to serve, not only as matrix-producing cells, but also as
key regulators of the inﬂammatory and reparative response following
cardiac injury. The current review manuscript will discuss the contri-
bution of ﬁbroblasts in the phases of healing following infarction and
the mechanisms involved in their phenotypic transitions.
Table 1
Phenotypic and functional alterations of the ﬁbroblasts in the healing infarct.
Cell phenotype Activity Modulators of ﬁbroblast phenotype Gene expression
Inﬂammatory phase Inﬂammatory ﬁbroblasts Activation of the inﬂammasome Reactive oxygen, IL-1β, TNF-α, IL-6,
oncostatin-M matrix fragments
Cytokine and chemokine synthesis,
expression of proteases.
Proliferative phase Activated myoﬁbroblasts Migration, proliferation, increased
capacity for wound contraction,
recruitment of ﬁbroblast progenitors,
endothelial to mesenchymal transition
(EndMT)
Angiotensin II, TGF-β, PDGFs, FGFs,
IL-10, tryptase/chymase, matricellular
protein/growth factor/integrin
interactions, ﬁbronectin ED-A
Collagen synthesis, expression of
matricellular proteins, synthesis of
contractile proteins (α-SMA),
expression of MMPs and TIMPs
Maturation phase “Quiescent” ﬁbroblast Apoptosis, loss of myoﬁbroblast
phenotype (?)
Withdrawal of growth factors and
removal of matricellular proteins,
unknown inhibitory and
pro-apoptotic signals.
Reduced matrix synthesis (?),
decreased α-SMA expression (?),
activation of pro-apoptotic genes (?)
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Although ﬁbroblasts clearly represent the predominant non-
cardiomyocyte population in the adult mammalian heart, their exact
contribution in the cellular composition of the heart varies from species
to species [1] and may also be dependent on age, gender and genetic
background. Early studies using scanning and transmission electronmi-
croscopy as well as gradient centrifugation demonstrated that approxi-
mately 70% of cells in the adult rat heart are non-cardiomyocytes [9,10];
themajority of these cells are ﬁbroblasts. In adultmouse hearts, ﬂuores-
cence activated cell sorting (FACS) analysis of single cell suspensions
demonstrated that ﬁbroblasts accounted for about 30% of the total
cells [11]. Fibroblasts are deﬁned as cells of mesenchymal origin with
the capacity to produce extracellularmatrix proteins. However, because
matrix protein expression is dependent on the level of cellular activa-
tion and matrix proteins can be synthesized by other cell types (such
as smoothmuscle cells), identiﬁcation of ﬁbroblasts in themyocardium
is usually based on morphological criteria. The absence of a basement
membrane is one of the deﬁning features of ﬁbroblasts that distinguish
them from other myocardial interstitial cells.
Study ofﬁbroblasts in tissues has been hampered by the absence of a
ﬁbroblast-speciﬁc surfacemarker. The cytoskeletal protein vimentin, an
intermediate ﬁlament protein expressed by mesenchymal cells, has
been extensively used to identify ﬁbroblasts in normal and injured
myocardium [12,13], but lacks speciﬁcity and is also expressed by vas-
cular endothelial and smooth muscle cells. Fibroblast-speciﬁc protein
(FSP)-1/S100A4 has been proposed as a ﬁbroblast marker [14] and
has been extensively used for ﬁbroblast speciﬁc gene disruption [15];
however, a growing body of evidence challenges its speciﬁcity sug-
gesting that it may be also expressed by lymphocytes, monocytes/
macrophages and smooth muscle cells [16–19]. Immunohistochem-
ical studies using both human and rat myocardial samples suggested
that, although in normal hearts FSP-1/S100A4 appears to be
expressed by ﬁbroblast-like cells, following myocardial injury
FSP-1 is predominantly localized in non-ﬁbroblasts. In the infarcted
and pressure-overloaded myocardium, leukocytes, endothelial cells
and smooth muscle cells, as well as ﬁbroblasts, exhibited FSP-1 ex-
pression, highlighting the low speciﬁcity of this marker [17].
Cadherin-11 is a protein expressed predominantly by mesenchymal
cells [20]; however, its potential role as a ﬁbroblast marker in normal
and injured hearts remains unclear. The collagen receptor discoidin
domain receptor (DDR)2 has been identiﬁed as a speciﬁc marker
for ﬁbroblasts in the developing and adult rat heart [21]; however,
its sensitivity and its ability to detect injury-site myoﬁbroblasts
have not been systematically studied. The matricellular protein
periostin is selectively upregulated in activated myoﬁbroblasts inﬁl-
trating the infarcted and pressure-overloaded heart and may be a
promising marker for the identiﬁcation of activated ﬁbroblasts fol-
lowing cardiac injury [22]. α-Smooth muscle actin (α-SMA), a pro-
tein abundantly expressed in smooth muscle cells, is not found in
normal cardiac ﬁbroblasts, but is markedly upregulated intransdifferentiated myoﬁbroblasts in the infarcted and remodeling
myocardium [13]. Despite its lack of speciﬁcity, α-SMA expression
is a useful marker for injury-site myoﬁbroblasts that can be distin-
guished from smooth muscle cells on the basis of their location and
morphology. Considering the extensive heterogeneity exhibited by
ﬁbroblasts, development of a single marker to label all ﬁbroblasts
may not be realistic. Identiﬁcation of ﬁbroblast subpopulations
with distinct functional properties and phenotypic characteristics is
a promising direction of research and could reﬁne our understanding
of ﬁbroblast biology.
In normal adult mammalian myocardium, ﬁbroblasts are inter-
spersed within the collagenous matrix network, often surrounding
cardiomyocytes and bridging myocardial tissue layers [23]. Despite
the abundance of ﬁbroblasts in the myocardium, relatively little is
known on their function in the absence of injury. In the developing
heart, embryonic cardiac ﬁbroblasts promote cardiomyocyte prolifera-
tion through interactions that involved β1 integrin signaling [24]. In
the adult heart, cardiac ﬁbroblasts are viewed as quiescent cells that
contribute to cardiac homeostasis mostly by maintaining the matrix
network. However, a growing body of evidence suggests that
intercellular communications between ﬁbroblasts and cardiomyocytes
may contribute to normal electrical and mechanical function of the
heart. Cardiac ﬁbroblasts express connexins in vivo and form highly
coupled ﬁbroblast:ﬁbroblast and ﬁbroblast:cardiomyocyte networks
[25]. Moreover, ﬁbroblasts are mechanosensitive and may provide in-
dependent sensors of the mechanical environment [26]. Although
mechanoelectric ﬁbroblast–cardiomyocyte interactions may be impor-
tant inﬁbrotic cardiac conditions [27], their contribution in normal ven-
tricular function has not been established.
3. The reparative response following myocardial
infarction: an overview
In myocardial infarction, death of a large number of cardiomyocytes
within a very short period of time poses a great challenge for the repar-
ative mechanisms of the body. Because the adult mammalian heart has
negligible regenerative capacity, myocardial necrosis triggers an in-
ﬂammatory/reparative response that removes dead cells and matrix
debris and replaces them with a collagen-based scar. Infarct healing is
associated with profound molecular and cellular changes in both the
infarcted and non-infarcted area and causes extensive alterations in
ventricular geometry, termed cardiac remodeling.
For descriptive purposes repair of the infarcted heart can be divid-
ed into three distinct, but overlapping phases: the inﬂammatory, pro-
liferative and maturation phase [28,29]. Intracellular contents
released from necrotic cells act as “danger signals” and activate innate
immunemechanisms, initiating an intense, but transient inﬂammato-
ry response. Toll like receptor (TLR)-mediated pathways, the comple-
ment cascade and reactive oxygen generation induce nuclear factor
(NF)-κB activation in resident myocardial cells, leading to chemokine
and cytokine synthesis [30]. Release of pro-inﬂammatory mediators
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into the infarcted myocardium [31,32]; activated leukocytes clear the
wound phagocytosing dead cells and matrix debris. Meanwhile, mac-
rophages release cytokines and growth factors leading to the forma-
tion of granulation tissue.
As the infarct is cleared from dead cells and matrix fragments, the
inﬂammatory response is suppressed. Neutrophils become apoptotic
and are phagocytosed by macrophages, reparative monocytes are
recruited [32], while lymphocytes and macrophages produce inhibi-
tory mediators capable of suppressing pro-inﬂammatory signals,
such as interleukin (IL)-10 and transforming growth factor (TGF)-β.
Suppression of the inﬂammatory reaction is followed by inﬁltration
of the infarct with ﬁbroblasts and endothelial cells marking the tran-
sition to the proliferative phase. Transdifferentiation of ﬁbroblasts
into myoﬁbroblasts is a prominent characteristic of the proliferative
phase [33,13]; infarct myoﬁbroblasts express α-SMA and other con-
tractile proteins [13], synthesize and deposit matrix proteins and
are believed to be important for infarct contraction and structural in-
tegrity of the infarcted heart. Angiotensin II, and TGF-β1 are crucial
reparative and ﬁbrogenic mediators, stimulating both ﬁbroblast to
myoﬁbroblast transdifferentiation and collagen synthesis in the
healing infarct. Fibroblast proliferation and activation are associated
with intense angiogenesis [13,34] that serves to provide oxygen and
nutrients to the metabolically active wound.
As the infarct is ﬁlled with matrix, cellular proliferation is
suppressed and transition to the maturation phase follows. Fibro-
blasts become quiescent and undergo apoptosis, while some infarct
neovessels acquire a muscular coat and uncoated vessels regress
[34,35]. As the infarct matures, matrix cross-linking results in the for-
mation of a dense collagen-based scar.4. Fibroblasts during the inﬂammatory phase of cardiac repair
Because cardiomyocytes are particularly sensitive to ischemia,
prolonged cessation of blood ﬂow following coronary occlusion
causes extensive cardiomyocyte necrosis. In contrast, cardiac ﬁbro-
blasts are much less vulnerable to oxidant stress exhibiting little or
no DNA fragmentation after exposure to H2O2 [36]. Given their abun-
dance, their strategic location in the cardiac interstitium and their re-
sistance to ischemic death, ﬁbroblasts are ideally suited to sense
microenvironmental alterations following myocardial injury and to
initiate the inﬂammatory response. However, their relative contribu-
tion in activation of the post-infarction inﬂammatory cascade re-
mains poorly documented.
Several cell types have been proposed as effector cells in triggering
inﬂammatory signaling following myocardial infarction. Endothelial
cells [37] and resident cardiac mast cells [38] have been implicated
as important early sources of pro-inﬂammatory chemokines and cy-
tokines in the infarcted myocardium. Recent ﬁndings suggest direct
involvement of ﬁbroblasts in the activation of the post-infarction in-
ﬂammatory reaction (Fig. 1). In a mouse model of reperfused myocar-
dial infarction cardiac ﬁbroblasts activated the inﬂammasome [39],
the molecular platform responsible for activation of inﬂammatory
caspases and for generation of active IL-1β. In vitro, activation of the
inﬂammasome in cardiac ﬁbroblasts was mediated through reactive
oxygen species (ROS) production and potassium efﬂux.
Hypoxia and reoxygenation are major stimuli mediating cellular
alterations in the ischemic and reperfused myocardium. In vitro, car-
diac ﬁbroblasts respond to hypoxia by acquiring a pro-inﬂammatory
and ﬁbrogenic phenotype characterized by enhanced cytokine ex-
pression [40], myoﬁbroblast transdifferentiation [41] and increased
collagen synthesis [42]. In contrast, hypoxia-mediated actions on ﬁ-
broblast proliferation and on matrix metabolism appear inconsistent
and gender-dependent [43–46]. On the other hand, reoxygenation
of cardiac ﬁbroblasts during reperfusion results in a state of“perceived hyperoxia” [47], enhances ﬁbroblast proliferation and is
a potent stimulus for increased extracellular matrix turnover [48].
Whichmolecular signals activate ﬁbroblasts during the inﬂammato-
ry phase of cardiac repair? Fibroblasts are highly responsive to ROS;
thus, accentuated free radical generation in the ischemic and reperfused
myocardium may play an important role in ﬁbroblast activation. ROS
modulate ﬁbroblast function both through direct actions and through
their involvement in cytokine signaling. Stimulation of cardiac ﬁbro-
blasts with brief oxidant stress leads to transient phosphorylation of
p38 and ERK1/2 and results in a phenotype characterized by increased
necrosis, reduced apoptosis, and impaired migratory capacity [49].
Moreover, oxidative stress regulates the quantity and quality of the ex-
tracellular matrix by modulating both collagen synthesis and metabo-
lism. Published studies provide contradictory evidence on the effects
of reactive oxygen on ﬁbroblast-derived matrix protein synthesis. Ex-
periments using neonatal and adult rat cardiac ﬁbroblasts demonstrat-
ed that reactive oxygen decreases collagen synthesis and increases
MMPactivity [50]. In contrast, other investigations using adult rat cardi-
ac ﬁbroblasts showed that ROS enhance collagen synthesis [51] and in-
crease expression of the matricellular protein osteopontin [52]. ROS
may also trigger matrix-preserving pathways by activating TGF-β, by
enhancing TGF-β actions [53], and by upregulating connective tissue
growth factor (CTGF) expression [54].
The cytokine-rich environment in the infarcted heart may also play a
role in the activation of ﬁbroblasts during the inﬂammatory phase of car-
diac repair. In vitro studies have demonstrated that IL-1α, tumor necrosis
factor (TNF)-α andoncostatin-Mpromote an inﬂammatory phenotype in
cardiac ﬁbroblasts inducing cytokine and chemokine syntheses [55–57].
In addition, cytokines are potent regulators of collagen metabolism and
profoundly affect ﬁbroblast-derived expression of matrix-degrading pro-
teases [58]. TNF-α, IL-1β and IL-6, allmarkedly upregulated in the infarct-
ed myocardium [28], decrease collagen synthesis in isolated cardiac
ﬁbroblasts and increase matrix metalloproteinase (MMP) expression
and activity, while reducing synthesis of inhibitors of metalloproteinases
[59]. Loss of IL-1 signaling in mice lacking the type 1 IL-1 receptor
(IL-1R1), the only signaling receptor for IL-1, is associated with attenuat-
ed MMP expression and activity in the remodeling infarcted heart [60].
The effects of IL-1/IL-1R1 in the infarcted myocardiummay be mediated
at least in part, through activation of ﬁbroblast-derived protease activity
[61]. IL-1β, and (to a lesser extent) TNF-α, but not IL-6, stimulate
concentration-dependent increases in cardiac ﬁbroblast migration [62].
Furthermore, IL-1β exerts potent antiproliferative effects on cardiac ﬁ-
broblasts [63] altering expression of ﬁbroblast cyclins, cyclin-dependent
kinases and their inhibitors [64].
5. Phenotypic modulation of ﬁbroblasts during the proliferative
phase of cardiac repair
The transition from the inﬂammatory to the proliferative phase is
associated with the activation of STOP signals that inhibit inﬂamma-
tion [65], while promoting ﬁbrous tissue deposition and angiogenesis.
Inhibitory cytokines, such as IL-10 and TGF-β, appear to play an im-
portant role in repressing the synthesis of pro-inﬂammatory cytokines
and chemokines [66,67]. Although many cell types participate in the
inhibition of pro-inﬂammatory cascades, inhibitorymonocyte, macro-
phage and lymphocyte subpopulations [32,68,69] are ideally suited as
effectors of suppression and resolution of inﬂammation following in-
farction.Whether ﬁbroblasts contribute to resolution of the inﬂamma-
tory reaction through secretion of inhibitory and pro-resolving
mediators remains unknown. Moreover, signals that may be responsi-
ble for the deactivation of inﬂammatory signaling in ﬁbroblasts have
not been systematically investigated. What is clear is that during the
proliferative phase of healing, ﬁbroblasts become the dominant cells
in the infarcted myocardium and are the key cell type in matrix secre-
tion and metabolism. During the proliferative phase cardiac ﬁbro-
blasts undergo dramatic phenotypic and functional changes: high
Fig. 1. The ﬁbroblast during the inﬂammatory phase of cardiac repair. The strategic location of cardiac ﬁbroblasts allows them to serve as sentinel cells, capable of sensing myocar-
dial injury and initiating pro-inﬂammatory cascades. In the infarcted myocardium ﬁbroblasts activate the inﬂammasome and may secrete cytokines and chemokines. Reactive ox-
ygen species (ROS), pro-inﬂammatory cytokines and matrix fragments may play a role in inﬂammatory activation of ﬁbroblasts. Several other cell types are capable of initiating and
propagating the post-infarction inﬂammatory reaction; the relative contribution of ﬁbroblasts is unclear.
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notype and augmented matrix-synthetic capacity are the main char-
acteristics of ﬁbroblasts during the proliferative phase of infarct
healing (Fig. 2).
5.1. Characteristics and origin of myoﬁbroblasts
During the proliferative phase of healing, the infarct is populatedwith
abundant phenotypically modulated ﬁbroblasts, termed myoﬁbroblasts.
These cells combine ultrastructural and phenotypic characteristics of
smooth muscle cells, acquired through formation of contractile stress ﬁ-
bers, with an extensive endoplasmic reticulum, a feature of synthetically
active ﬁbroblasts [70,71]. Expression of α-SMA is considered the hall-
mark for differentiated myoﬁbroblasts. α-SMA-positive myoﬁbroblasts
in the healing infarct also synthesize other contractile proteins, such asFig. 2. Phenotypic modulation and activation of ﬁbroblasts during the proliferative phase of c
as expression of the ED-A ﬁbronectin variant) and mechanical stress due to matrix degrada
the healing wound stimulates matrix protein synthesis by infarct myoﬁbroblasts.non-muscle myosin, but are distinguished from smooth muscle cells be-
cause they do not express desmin, smoothelin and smooth muscle myo-
sin heavy chain [33,72,13,73]. Although α-SMA expression increases
cellular contractile activity, it is not a requirement for the myoﬁbroblast
phenotype. At the early stages of the healing process myoﬁbroblasts
have stress ﬁbers composed of cytoplasmic actins, while lacking α-SMA
expression; these cells are termed proto-myoﬁbroblasts [74]. Proto-
myoﬁbroblasts develop mature focal adhesions containing β- and
γ-actin microﬁlaments that are associated with nonmuscle myosin [74].
The origin of myoﬁbroblasts in the infarcted myocardium remains
controversial. Given the abundance of ﬁbroblasts in the cardiac inter-
stitium and the marked induction of signals promoting myoﬁbroblast
transdifferentiation in thehealing infarct (such as TGF-β1), resident cardi-
ac ﬁbroblasts likely represent the most important source of myoﬁbro-
blasts in cardiac repair. A study using bone marrow transplantationardiac repair. Activation of TGF-β signaling, alterations in the extracellular matrix (such
tion induce myoﬁbroblast transdifferentiation. The growth factor-rich environment of
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suggested that proliferation of resident cardiac ﬁbroblasts is the main
source of myoﬁbroblasts in the healing infarct [75]. Studies in models of
infarctive and non-infarctive cardiac ﬁbrosis have suggested the role of
hematopoietic cells and endothelial cells as potential sources of ﬁbro-
blasts in the ﬁbrotic myocardium. In a model of interstitial ﬁbrosis due
to brief repetitive myocardial ischemia and reperfusion [76], recruitment
of blood-derived ﬁbroblast progenitors has been identiﬁed as a mecha-
nism involved in ﬁbroblast inﬁltration [77]. Moreover, bone marrow
transplantation experiments using enhanced GFP (eGFP)-labeled cells
demonstrated numerous bone marrow-derived ﬁbroblasts in the infarct-
ed myocardium [78]. Recently, endothelial to mesenchymal transition
was found to contribute to cardiac ﬁbrosis inmodels of pressure overload
and chronic allograft rejection [79]. Using Tie1Cre;R26RstoplacZ mice, in
which endothelial cells and their descendants are marked by LacZ, and
FSP-1-GFP transgenic mice, Zeisberg and co-workers demonstrated that
a substantial fraction of activated ﬁbroblasts in the ﬁbrotic heart were of
endothelial origin [79]. However, concerns regarding the poor speciﬁcity
of FSP-1 as a ﬁbroblast marker and the possibility that ectopic expression
of Cre activity may be induced in sites of injury [80] may limit the signif-
icance of the ﬁndings.
5.2. The molecular signals mediating myoﬁbroblast transdifferentiation
Generation of α-SMA-positive differentiated myoﬁbroblasts re-
quires the cooperation between TGF-β signaling, mechanical stress
and specialized matrix proteins, such as the ED-A ﬁbronectin variant
[74]. TGF-β is induced and activated in the infarcted myocardium and
promotes α-SMA transcription in ﬁbroblasts through the activation of
the Smad3 signaling cascade [29]. Alterations in the composition and
mechanical properties of the extracellularmatrix also play an important
role inmyoﬁbroblast transdifferentiation. The splice variant ED-Aof cel-
lular ﬁbronectin is upregulated in the infarcted heart [81] and mediates
acquisition of the myoﬁbroblast phenotype [82,83]. Increased deposi-
tion of non-ﬁbrillar collagens (such as collagen VI) in the infarctedmyo-
cardium may also modulate myoﬁbroblast transdifferentiation [84]. In
vitro, type VI collagen potently induces myoﬁbroblast differentiation,
but has little effect on ﬁbroblast proliferation [84]. In vivo, collagen VI
disruption attenuated ﬁbrosis and improved cardiac function in a
model of myocardial infarction. However, the beneﬁcial effects of
collagen VI loss on the infarcted heart may, in addition to inhibition
of ﬁbrosis, also involve a reduction in cardiomyocyte apoptosis
[85]. Mechanical stress also directly stimulates α-SMA transcription
through Rho/Rho kinase signaling [86], but is not sufﬁcient to induce
myoﬁbroblasts transdifferentiation in the absence of TGF-β. In nor-
mal hearts, ﬁbroblasts are generally protected from mechanical stimuli
by a stable cross-linkedmatrix network. Once the structural integrity of
the myocardium is disrupted, exposure of the cells to mechanical stress
contributes to proto-myoﬁbroblast transdifferentiation [74].
5.3. Migration of ﬁbroblasts into the infarct
Although migration of myoﬁbroblasts into the region of
cardiomyocyte loss is important for scar formation, the molecular sig-
nals implicated in ﬁbroblast migration remain poorly understood.
Chemokines provide essential signals for leukocyte recruitment
[30]; however, whether chemokine/chemokine receptor interactions
also stimulate ﬁbroblast chemotaxis is unknown. Some members of
the chemokine family, such as monocyte chemoattractant protein
(MCP)-1/CCL2 may induce migration of ﬁbroblast progenitors into
the infarcted heart. Growth factors, such as TGF-β and ﬁbroblast
growth factors (FGFs), may also trigger migration of ﬁbroblasts into
the site of injury. Clearly, remodeling of the healing infarct requires
a highly plastic microenvironment that supports ﬁbroblast motility.
In order to move into the site of injury, myoﬁbroblasts must continu-
ally form and disrupt adhesive interactions with the surroundingmatrix.Movement of ﬁbroblasts through thematrix requires integrin ac-
tivation on the surface of ﬁbroblasts, production of proteases capable of
degrading matrix components and deposition of matricellular proteins
into the cardiac interstitium that promote a “deadhesive” state, thus fa-
cilitating migration [87,88]. Migration of myoﬁbroblasts to the damaged
region is associated with expression of frizzled-2 (fz2), a tissue polarity
gene that determines planar polarity during embryonic development
[89]. Blockade of the frizzled pathway using a peptide fragment of
wnt3/wnt5 increased myoﬁbroblast density in the infarct and pre-
served cardiac function following myocardial infarction [90].
In addition to pro-migratory pathways, inhibitory signals that
attenuate ﬁbroblast migration are also activated in the infarcted
myocardium, presumably acting to prevent an overactive, or expanded,
ﬁbrotic response. The CXC chemokine CXCL10/Interferon-γ-inducible
Protein (IP)-10 is upregulated in the infarctedmyocardium [91] and in-
hibits growth factor-induced ﬁbroblast migration preventing excessive
ﬁbrotic remodeling of the infarcted heart [92].
5.4. Mediators involved in activation of a ﬁbrogenic program
Infarct myoﬁbroblasts are the predominant source of matrix protein
synthesis in healing myocardial infarcts [93–96]. During the proliferative
phase of healing, the infarctmicroenvironment is rich inﬁbrogenic growth
factors that enhanceproliferative activity and increase thematrix synthetic
capacity of infarct myoﬁbroblasts. Angiotensin II may play an important
role in infarct ﬁbroblast proliferation and matrix synthesis, mediating ef-
fects transduced through AT1 receptors [97]. The effects of angiotensin II
may be mediated, at least in part, through induction of growth factors,
such as TGF-β, FGF-2 and platelet-derived growth factor (PDGF), that are
also released in the infarcted myocardium andmay induce ﬁbroblast pro-
liferation andactivation [98,35]. PDGF signaling is involved inmatrix depo-
sition in the healing infarct; antibody neutralization of PDGF-Rα, or
PDGF-Rβ-mediated interactions attenuates collagen accumulation in the
infarcted heart [35]. However, the effects of PDGF on infarct healing are
not only due to ﬁbroblast-mediated actions, PDGF-Rβ, but not PDGF-Rα
neutralization, results in defective pericyte recruitment and impaired vas-
cular maturation following myocardial infarction [35]. Moreover, the
mast-cell derived proteases tryptase and chymase have potent ﬁbrogenic
properties andmay also be involved in stimulating ﬁbroblast synthetic ac-
tivity in the infarct [99]. Althoughmultiple molecular signals are likely in-
volved in ﬁbroblast activation in the healing infarct, the bulk of the
evidence suggests a major role for TGF-β.
5.5. The role of TGF-β in activation of cardiac ﬁbroblasts in the infarcted
myocardium
TGF-β is a multifunctional and highly pleiotropic growth factor
with a broad range of effects on cell proliferation, migration, differen-
tiation, and apoptosis. In mammals TGF-β is found in three isoforms
(TGF-β1, 2 and 3), encoded by three distinct genes [100]; TGF-β1 is
the prevalent and best-studied isoform. TGF-β is produced by many
cell types as a latent propeptide, which is covalently bound to the la-
tency associated peptide (LAP) to form an inactive complex, unable to
associate with its receptors. Most tissues contain large amounts of la-
tent TGF-β; activation of only a small fraction of latent TGF-b is sufﬁ-
cient to generate maximal cellular response [101]. As part of the
latent complex, TGF-β is inactive, because the non-covalent high-
afﬁnity association between the LAP and TGF prevents TGF-β binding
to its receptor. Activation of TGF-β involves liberation of the TGF-β
dimer from the activation-competent LAP:TGF-β complex.
TGF-β activation involves protease-mediated actions. Plasmin,MMP-2
andMMP-9, are capable of activating TGF-β, couplingmatrix degradation
with activation of a molecule with potent matrix-preserving effects
[101–103]. Moreover, the matricellular protein thrombospondin (TSP)-1
is a key TGF-β activator which acts by disrupting the non-covalent LAP:
TGF-β interaction [104]. Integrins are also involved in TGF-β activation
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tating enzymatic cleavage of the latent complex, or by altering latent
TGF-β conformation [105].
Active TGF-β binds to the constitutively active type II receptor
(TβRII) at the cell surface, then interacts with, and transphosphorylates
the cytoplasmic domain of the type I receptor (TβRI) propagating
downstream intracellular signals, through the Smad proteins [106]. Sig-
naling though Smad3 is implicated in the development of ﬁbrosis [107].
In addition to canonical Smad activation, TGF-β also signals through
Smad-independent pathways [108].
TGF-β expression is markedly upregulated following infarction
and is predominantly localized in the infarct border zone, associated
with enhanced phosphorylation of its downstream effectors Smad2/
3 [109]. TGF-β has profound effects on ﬁbroblast phenotype and
gene expression andmay induce cardiac ﬁbrosis through several dis-
tinct mechanisms [110]. TGF-β stimulation induces myoﬁbroblast
differentiation [111] and promotes extracellular matrix protein syn-
thesis. In addition, TGF-β exerts matrix-preserving actions primarily
by inducing synthesis of protease inhibitors, such as plasminogen ac-
tivator inhibitor (PAI)-1 and tissue inhibitors of metalloproteinases
(TIMPs) [100]. The ﬁbrogenic actions of TGF-β are mediated at least
in part through induction of CTGF [110], a member of the CCN family
of matricellular proteins that promotes ﬁbroblast proliferation and
stimulates matrix deposition. In vivo, two independent studies
using gene transfer strategies to inhibit TGF-β signaling suggested
an important role for TGF-β in ﬁbrous tissue deposition following
myocardial infarction [112,113]. TGF-β inhibition resulted in de-
creased ﬁbrous tissue deposition in the infarcted area. Timing of the in-
tervention may be a critical determinant of outcome. Early TGF-β
inhibition may prevent important suppressive effects of TGF-β on the
post-infarction inﬂammatory response, resulting in increasedmortality
and exacerbated left ventricular dilation [113,114]. In contrast, late
TGF-β inhibition may be protective by attenuating pro-ﬁbrotic effects.
TGF-β-mediated ﬁbroblast activation in the infarcted heart may
involve several distinct pathways. The Smad3 pathway plays an es-
sential role in ﬁbrotic remodeling of the infarcted ventricle [109]. Re-
duction of interstitial ﬁbrosis in Smad3 null mice prevented the
development of diastolic dysfunction following myocardial infarction.
The anti-ﬁbrotic effects of Smad3 deﬁciency were not due to reduced
ﬁbroblast inﬁltration into the infarct. In vivo, myoﬁbroblast density in
the infarcted myocardium was signiﬁcantly higher in Smad3 null in-
farcts, and in vitro TGF-β exerted Smad3-dependent antiproliferative
actions on cardiac ﬁbroblasts [115]. However, Smad3 loss was associ-
ated with functional impairment of ﬁbroblasts inﬁltrating the infarct.
TGF-β-mediated upregulation of extracellular matrix protein synthe-
sis in cardiac ﬁbroblasts was dependent on Smad3, suggesting that
decreased ﬁbrotic remodeling in infarcted Smad3 null hearts may
be due to abrogation of the pro-ﬁbrotic TGF-β responses. Moreover,
TGF-β-induced α-SMA upregulation and incorporation into the cyto-
skeleton was also dependent on Smad3 [115]. Thus, the Smad3 path-
way is essential for the development of ﬁbrosis and diastolic
dysfunction following infarction through effects on activation and
transdifferentiation of ﬁbroblasts.
Much less is known regarding the role of Smad-independent pathways
in ﬁbrous tissue deposition in the heart. An activating mutation of TGF-β‐
activated kinase (TAK)-1 expressed in the myocardium produced marked
hypertrophy and interstitial ﬁbrosis associated with severe dysfunction,
suggesting that TGF-β/TAK-1 signaling exerts proﬁbrotic actions.However,
direct evidence supporting the involvement of Smad-independent path-
ways in ﬁbrosis of the infarcted ventricle is lacking.
6. The fate of the ﬁbroblasts during infarct maturation
As the myocardial scar matures, collagen content progressively in-
creases while leukocytes, vascular cells and ﬁbroblasts are cleared, pre-
sumably through apoptosis. Descriptive studies have demonstratedthat, after the end of the proliferative phase, myoﬁbroblast density in
the infarcted heart decreases with time [13]. Apoptosis may be respon-
sible for the elimination of mostmyoﬁbroblasts from themature infarct
[34,116,117]. Whether myoﬁbroblast deactivation precedes apoptosis
and clearance from the infarct remains unknown. Reduced levels of
growth factors, and clearance of matricellular proteins may deprive
scar ﬁbroblasts from key pro-survival and activation signals. Moreover,
changes in the composition of the matrix in the mature scar may have
profound consequences on ﬁbroblast phenotype. Formation of amature
cross-linked matrix may “shield” ﬁbroblasts from external mechanical
stress resulting in their deactivation [72,70]. Interactions of the ﬁbro-
blasts with a highly organized, cross-linked matrix network may pro-
mote stress ﬁber dissolution and cellular quiescence. It should be
noted that, after completion of the reparative response, ﬁbroblasts re-
siding in the remodeling non-infarcted myocardium may become
chronically activated in response to increased wall stress. These
non-reparative cells may contribute to chamber remodeling and ven-
tricular dysfunction by producing matrix proteins and proteases.
7. The ﬁbroblast as a therapeutic target following
myocardial infarction
As the main effector cells of the post-infarction reparative re-
sponse, cardiac ﬁbroblasts may be promising therapeutic targets. In
fact, established therapies for patients with post-infarction heart fail-
ure may act, at least in part, by attenuating ﬁbrotic remodeling of the
failing ventricle. Administration of angiotensin-converting enzyme
inhibitors reduces mortality and slows the progression of heart fail-
ure, while inhibiting cardiac ﬁbrosis [118]. Similarly, treatment with
aldosterone antagonists, or statins, reduces cardiac remodeling and
interstitial ﬁbrosis following myocardial infarction [119,120]. The ex-
tent to which these antiﬁbrotic actions contribute to improved clini-
cal outcome is unknown.
Animal model studies have identiﬁed promising new strategies
that may prevent adverse remodeling by modulating ﬁbroblast acti-
vation. Anti-IL-1 approaches may attenuate chamber dilation by lim-
iting ﬁbroblast-mediated inﬂammatory activity [121]. Peptides
blocking frizzled signaling may prevent expansion of the ﬁbrotic
area [90]. Considering the essential role of TGF-β1 as a regulator of ﬁ-
broblast phenotype and function, approaches interfering with TGF-β1
signaling may hold promise in prevention of ﬁbrotic cardiac remodel-
ing [122,109]. Because of the established role of Smad2/3 signaling in
cardiac ﬁbrosis, Smad3 inhibitors may be particularly promising.
However, several important issues need to be taken into account be-
fore designing therapeutic strategies aiming at modulating ﬁbroblast
function following infarction.
First, it should be emphasized that experimental studies cannot sim-
ulate the complexity and pathophysiologic heterogeneity of the clinical
context and do not predict clinical success. Variables such as age, gen-
der, the presence of comorbid conditions such as diabetes, obesity and
hyperlipidemia, the use of medications thatmay interfere with the pro-
posed pathway and genetic variations between individuals greatly
complicate prediction of the potential effects of a therapeutic interven-
tion. For example, aging is associated with impaired reparative reserve
[123]. Poor responsiveness of senescent ﬁbroblasts to growth factors
may result in the formation of defective scars exhibiting low collagen
content; these defects predispose to dilation. In contrast, in other pa-
tient subpopulations (such as diabetic patients), ﬁbroblast matrix syn-
thesis may be augmented leading to excessive ﬁbrosis and increased
ventricular stiffness associatedwith diastolic dysfunction. Development
and validation of speciﬁc biomarkers reﬂectingmatrix metabolismmay
lead to pathophysiologically-guided approaches in treatment of pa-
tients with myocardial infarction [124]. Second, interfering with ﬁbro-
blast activation in the context of the dynamic alterations associated
with healing infarction poses signiﬁcant challenges. Design of a thera-
peutic strategy needs to carefully consider spatial and temporal
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be detrimental when applied in the center of the infarct, by reducing
the tensile strength of the wound, thus accentuating adverse remodel-
ing [125]. Furthermore, the timing of the intervention is critical. Many
mediators involved in ﬁbroblast activation are also implicated in other
cellular processes with an essential role in cardiac repair. For example,
TGF-β blockade during the early post-ischemic phase accentuates ad-
verse remodeling by preventing timely resolution of the inﬂammatory
reaction [113]. On the other hand very late inhibition could be ineffec-
tive, as advanced ﬁbrosis and formation of a mature scar may no longer
be reversible. Thus the window of therapeutic opportunity in patients
with reparative ﬁbrosis is narrow and success of a speciﬁc intervention
may also depend on careful spatial localization of the antiﬁbrotic strat-
egy. Third, improved clinical outcome may depend on optimal regula-
tion of ﬁbroblast activity and matrix metabolism. Overzealous
inhibition of ﬁbroblast-derived matrix synthesis may reduce mechani-
cal support leading to chamber dilation and adverse remodeling. Suc-
cessful implementation of therapeutic approaches targeting the
ﬁbrotic responsemay require strategies to identify patients with specif-
ic pathophysiologic disturbances using both clinical criteria and bio-
chemical markers.
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